This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

plerixafor (Mozobil®)

Reference No. 3297

Publication date:

Appraisal information

plerixafor (Mozobil®) 20 mg/ml solution for injection

Company: Sanofi
BNF category: Nutrition and blood
NMG meeting date: 08/01/2020
AWMSG meeting date: 11/02/2020
Submission Type: Limited Submission
Status: Recommended
Advice No: 0120
Ratification by Welsh Government: 14/02/2020

Current Progress

Ratification by
Welsh Government

AWMSG advice

Plerixafor (Mozobil®) is recommended for use within NHS Wales in combination with granulocyte colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children aged ≥ 1 to <18 years with lymphoma or solid malignant tumours either: pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired haematopoietic stem cells yield, or; who previously failed to collect sufficient haematopoietic stem cells.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)